In 2007, the Ubiquitously Transcribed Tetratricopeptide Repeat on chromosome X (UTX) was identified as a histone demethylase that specifically targets di- and tri-methyl groups on lysine 27 of histone H3 (H3K27me2/3).Since then, UTX has been proven essential during normal development, as it is critically required for correct reprogramming, embryonic development and tissue-specific differentiation.UTX is a member of the MLL2 H3K4 methyltransferase complex and its catalytic activity has been linked to regulation of HOX and RB transcriptional networks.In addition, an H3K27me2/3 demethylase independent function for UTX was uncovered in promoting general chromatin remodeling in concert with the BRG1-containing SWI /SNF remodeling complex.Constitutional inactivation of UTX causes a specific hereditary disorder called the Kabuki syndrome, whereas somatic loss of UTX has been reported in a variety of human cancers.Here, we compile the breakthrough discoveries made from the first disclosure of UTX as a histone demethylase till the identification of diseaserelated UTX mutations and specific UTX inhibitors.© 2014 Landes Bioscience.
CITATION STYLE
Van Der Meulen, J., Speleman, F., & Van Vlierberghe, P. (2014, February 21). The H3K27me3 demethylase UTX in normal development and disease. Epigenetics. Taylor and Francis Inc. https://doi.org/10.4161/epi.28298
Mendeley helps you to discover research relevant for your work.